Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (cdc) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 5 Parkinson's papers of 4,331 | 0.76 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 7580
Sealed predictions
- CXCL9 in dopamine neurons, braak+0.45 (p 0.230) → +0.57 (p 0.111)receipt 7588
Swarm cases
receipt 7588: CXCL9 in dopamine neurons, braak
- power
- full sample +0.36 (p 0.148, n 18), 95% CI -0.13 to +0.71. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.32 (p 0.194, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.28 (p 0.258, n 18). could be the mix.
- skeptic
- leave-one-out range +0.28 to +0.52, sign flips 0; without severely affected donors +0.36 (p 0.148, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CXCL9 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts